Latest Licensing Deals News

AdAlta Limited has raised up to A$1.1 million through a private placement, boosting its war chest to advance innovative cellular immunotherapy projects targeting solid cancers.

Vectus Biosystems has had its ASX trading suspension lifted following the disclosure of a significant transaction involving a compound from its drug library, signaling renewed investor interest.

Vectus Biosystems has requested an immediate suspension of its ASX-listed shares pending a significant announcement about a transaction involving a compound in its drug library.

archTIS has secured a A$250,000 contract to develop new features for its NC Protect product tailored to the U.S. Department of Defense’s Microsoft DoD365 environment, reinforcing its foothold in the U.S. defense sector.

Elementos Limited has executed a binding option agreement to acquire half of Iberian Smelting SL, owner of the Robledollano Tin Smelter in Spain, setting the stage for the EU's first vertically integrated primary tin supply chain.

Invion Limited has secured $0.8 million through convertible notes to repay its Lind Global Fund II LP facility and support working capital, positioning itself for potential global licensing deals of its Photosoft technology.

InFocus Group Holdings has launched a dedicated iGaming business unit, aiming to capitalize on the booming $95 billion online gaming industry with key contracts and digital asset integration.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.